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OBJECTIVE — Subclinical inﬂammation represents a risk factor of type 2 diabetes and sev-
eral diabetes complications, but data on diabetic neuropathies are scarce. Therefore, we inves-
tigated whether circulating concentrations of acute-phase proteins, cytokines, and chemokines
differ among diabetic patients with or without diabetic polyneuropathy.
RESEARCH DESIGN AND METHODS — We measured 10 markers of subclinical
inﬂammation in 227 type 2 diabetic patients with diabetic polyneuropathy who participated
in the population-based MONICA/KORA Survey F3 (2004–2005; Augsburg, Germany).
Diabetic polyneuropathy was diagnosed using the Michigan Neuropathy Screening Instru-
ment (MNSI).
RESULTS — After adjustment for multiple confounders, high levels of C-reactive protein
andinterleukin(IL)-6weremostconsistentlyassociatedwithdiabeticpolyneuropathy,high
MNSI score, and speciﬁc neuropathic deﬁcits, whereas some inverse associations were seen
for IL-18.
CONCLUSIONS — This study shows that subclinical inﬂammation is associated with dia-
betic polyneuropathy and neuropathic impairments. This association appears rather speciﬁc
because only certain immune mediators and impairments are involved.
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S
ubclinicalinﬂammationisariskfac-
tor not only for type 2 diabetes (1)
but also for diabetes complications
such as cardiovascular disease, stroke, di-
abeticnephropathy,anddiabeticretinop-
athy (2–4). However, the association
betweensubclinicalinﬂammationanddi-
abetic polyneuropathy has only been in-
vestigated in small studies without
deﬁnitive results (5,6).
Therefore,theaimofthisstudywasto
investigate systematically whether pa-
tientswithtype2diabeteswithorwithout
diabetic polyneuropathy exhibit a differ-
ent immune proﬁle and whether associa-
tions between subclinical inﬂammation
and diabetic polyneuropathy as well as
the individual components of diabetic
polyneuropathy are independent of an-
thropometric and metabolic factors.
RESEARCH DESIGN AND
METHODS— Data are based on the
MONICA/KORASurveyF3study(2004–
2005). The present study includes 227
participants of the MONICA/KORA Sur-
vey F3 with type 2 diabetes. Diabetic
polyneuropathy was diagnosed based on
the Michigan Neuropathy Screening In-
strument (MNSI) (7). A cutoff of 2
points in the continuous MNSI score was
used as previously suggested (7–10) and
identiﬁed 111 individuals with diabetic
polyneuropathy. The study design; assess-
ment of neuropathic impairments; collec-
tionofinformationregardingdemographic,
anthropometric, clinical, sociodemo-
graphic, and lifestyle variables and medica-
tion; measurement of metabolic and
immune mediators markers; and statistical
analysis are described in the online appen-
dix (http://care.diabetesjournals.org/cgi/
content/full/dc08-2011/DC1).
RESULTS— The prevalence of dia-
betic polyneuropathy as deﬁned by an
MNSI score 2 was 48.9% (95% CI
42.4–55.4)inourstudypopulation(sup-
plementaryFigureA1andTableA1inthe
online appendix). Patients with diabetic
polyneuropathy had higher levels of
C-reactive protein (CRP) (P  0.013),
interleukin (IL)-6 (P  0.0091), and in-
terferon-–inducible protein-10 (P 
0.039) compared with those in patients
without diabetic polyneuropathy,
whereas leukocyte count and levels of se-
rum amyloid A, IL-18, tumor necrosis
factor-, adiponectin, IL-8, and mono-
cyte chemoattractant protein-1 did not
differ signiﬁcantly (Table A1).
BothCRP(r0.23;P0.0006)and
IL-6 (r  0.25; P  0.0001) were highly
signiﬁcantly associated with the continu-
ousMNSIscoreinunivariateanalysesand
in multiple linear regression models that
adjusted for anthropometric, metabolic,
and lifestyle factors; anti-inﬂammatory
medication; and recent respiratory infec-
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The most consistent associations with in-
dividual neuropathic deﬁcits were ob-
served for CRP and IL-6, and some
associations between IL-18 and neuro-
pathicdeﬁcitswerefound(Table1).High
levels of CRP or IL-6 were associated with
impaired ankle reﬂex, high vibration per-
ception threshold, abnormal appearance
of feet, and impaired pain perception
(pinprick).InthecaseofIL-18,lowlevels
of this cytokine were associated with im-
pairedanklereﬂexandimpairedpainper-
ception (pinprick). Associations for the
other immune markers were less pro-
nounced or absent (data not shown).
CONCLUSIONS — The present study
demonstrates for the ﬁrst time at the popu-
lation level that several immune mediators
are associated with diabetic polyneurop-
athy and that many of these associations
persistwhenadjustingformultiplepoten-
tialconfounders.CRPandIL-6weremost
consistently associated with diabetic
polyneuropathy and some neuropathic
deﬁcits. Although the strength of the cor-
relations with the MNSI score was mod-
erate (r  0.25), it is important that these
associations remained statistically signiﬁ-
cant after adjustment for multiple con-
founders, including duration of diabetes
and A1C, so that immune activation in dia-
betic polyneuropathy cannot be explained
solely as a consequence of hyperglycemia
or other metabolic disturbances. Associa-
tions of CRP and IL-6 with cardiac auto-
nomic neuropathy have been previously
reported in two small studies in patients
with type 1 diabetes (11,12). Further-
more,wedescribesigniﬁcantassociations
of subclinical inﬂammation with some of
the individual neuropathic impairments.
Interestingly, impaired temperature per-
ception and pain or discomfort in the
lower limbs were not associated with any
of the measured immune mediators, indi-
cating that the association between sub-
clinical inﬂammation and diabetic
polyneuropathy may only affect certain
components of diabetic polyneuropathy,
whereas others may be independent of
immune activation.
The association between subclinical
inﬂammation and diabetic polyneurop-
athy appears relatively complex because
higher CRP and IL-6 levels were associ-
ated with diabetic polyneuropathy,
whereas for IL-18, an inverse association
was found. CRP is an acute-phase protein
that is produced in the liver, and its main
inducer is IL-6. This relationship is re-
ﬂected by the high degree of correlation
between these two mediators in the
presentstudy(r0.56;P0.001)(sup-
plementary Table A2). Because IL-18 is
Table 1—Association among MNSI, individual components of diabetic polyneuropathy, and immunological variables (multivariable-adjusted
analysis)
Dependent variable Model 1 Model 2 Model 3 Model 4
 P  P  P  P
MNSI score
CRP (mg/l) 0.17 0.0005 0.14 0.0043 0.14 0.0055 0.14 0.0067
IL-6 (pg/ml) 0.09 0.0015 0.08 0.0082 0.08 0.0090 0.08 0.0076
IL-18 (pg/ml) 0.03 0.13 0.03 0.15 0.03 0.094 0.03 0.11
Ankle reﬂex score
CRP (mg/l) 0.14 0.0037 0.10 0.060 0.09 0.076 0.09 0.086
IL-6 (pg/ml) 0.08 0.0058 0.05 0.080 0.05 0.087 0.06 0.079
IL-18 (pg/ml) 0.05 0.012 0.04 0.023 0.05 0.014 0.05 0.013
Vibration perception score
CRP (mg/l) 0.01 0.075 0.008 0.23 0.008 0.23 0.007 0.28
IL-6 (pg/ml) 0.01 0.0036 0.008 0.034 0.008 0.031 0.008 0.035
IL-18 (pg/ml) 0.003 0.22 0.002 0.34 0.002 0.31 0.003 0.26
Temperature perception score
CRP (mg/l) 0.04 0.39 0.05 0.23 0.06 0.17 0.06 0.21
IL-6 (pg/ml) 0.04 0.18 0.04 0.17 0.04 0.15 0.04 0.13
IL-18 (pg/ml) 0.01 0.35 0.02 0.22 0.02 0.25 0.02 0.31
Appearance of feet
CRP (mg/l) 0.39 0.010 0.36 0.019 0.34 0.026 0.36 0.024
IL-6 (pg/ml) 0.20 0.037 0.19 0.041 0.19 0.047 0.20 0.040
IL-18 (pg/ml) 0.03 0.65 0.01 0.85 0.004 0.95 0.004 0.94
Pain perception (pinprick)
CRP (mg/l) 0.11 0.55 0.003 0.99 0.01 0.94 0.03 0.88
IL-6 (pg/ml) 0.25 0.023 0.20 0.082 0.20 0.076 0.20 0.085
IL-18 (pg/ml) 0.15 0.021 0.14 0.045 0.13 0.059 0.15 0.035
Pain or discomfort in the lower limbs
CRP (mg/l) 0.06 0.74 0.04 0.79 0.05 0.76 0.11 0.52
IL-6 (pg/ml) 0.06 0.59 0.06 0.53 0.06 0.55 0.07 0.53
IL-18 (pg/ml) 0.10 0.095 0.11 0.087 0.10 0.10 0.10 0.10
Regression coefﬁcients  and P values for MNSI score and individual impairments are from multiple linear regression models with ln-transformed concentrations
of immune mediators as dependent variables. Details on the assessment of neuropathic deﬁcits are given in the online appendix. Model 1: adjusted for age and sex;
model 2: adjustment for model 1 variables plus waist circumference, duration of diabetes, A1C, hypertension, and total cholesterol; model 3: adjustment for model
2 variables plus smoking, high alcohol intake, and physical activity; model 4: adjustment for model 3 variables plus lipid-lowering medication, nonsteroidal
anti-inﬂammatory drugs, and recent respiratory infections.
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tory cytokine (13), the hypothesis of
IL-18 being protective against at least
some neurological symptoms (14,15)
needs to be corroborated by further
studies.
The population-based design of the
MONICA/KORASurveyF3,theextensive
immunological phenotyping, and the
multiple regression analyses represent
strengthsofthisstudy.Thisstudyalsohas
limitations. First, MNSI as a diagnostic
tool only allows identiﬁcation of patients
with high risk of diabetic polyneurop-
athy.Althoughmostpatientswillhavedi-
abetic polyneuropathy, in some cases
neuropathy may not have been due to di-
abetes,butanexclusionofotherpotential
causes of neuropathy for this relatively
largestudysamplewasnotfeasible.How-
ever, MNSI has been validated in other
diabetic populations (7–10). In addition,
we did not conduct more objective elec-
trophysiological tests to assess neuro-
pathic deﬁcits, which could have had an
impact on our ﬁndings. Second, this
study is cross-sectional, so one cannot
distinguish between true risk factors and
associations that could be due to reverse
causation or simply coincidental. Third,
the study lacked a nondiabetic control
group, which would have been necessary
to demonstrate unequivocally that the di-
abetic study participants had increased
levels of proinﬂammatory markers com-
pared with those in healthy individuals
withouttype2diabetes.Fourth,thestudy
relied on measurements of immune me-
diators at a single time point only and at
differentstagesofdisease.Fifth,thestudy
was not designed to assess neuropathic
pain in detail; thus, further studies are
necessary to clarify the association be-
tween subclinical inﬂammation and this
speciﬁc neuropathic symptom. Sixth, we
performed multiple tests in this study, so
type I errors cannot be ruled out.
Taken together, the data indicate that
diabetic polyneuropathy and some of its
individual impairments are signiﬁcantly
associated with subclinical inﬂammation
(in particular with CRP, IL-6, and, in-
versely, IL-18). Prospective studies will
be required to assess the time course and
causal relevance of subclinical inﬂamma-
tion in the development of diabetic poly-
neuropathy in order to test whether
immunomodulation could become a
treatment option for patients with dia-
betic polyneuropathy.
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